Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Repligen (RGEN)
Repligen Analyst Ratings
RBC Capital Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $205
Craig-Hallum Maintains Repligen(RGEN.US) With Buy Rating
Craig-Hallum Sticks to Their Buy Rating for Repligen (RGEN)
Wells Fargo Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $180
Analysts' Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA) and Repligen (RGEN)
Wells Fargo Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $180
Jefferies Upgrades Repligen(RGEN.US) to Buy Rating, Raises Target Price to $180
Repligen Price Target Announced at $180.00/Share by Wells Fargo
Repligen Initiated at Overweight by Wells Fargo
Repligen Analyst Ratings
Wells Fargo Initiates Coverage On Repligen With Overweight Rating, Announces Price Target of $180
Buy Rating Affirmed: Overlooked Long-Term Benefits of Repligen's Potential Maravai Acquisition
Jefferies Maintains Repligen(RGEN.US) With Hold Rating, Cuts Target Price to $160
Jefferies Remains a Hold on Repligen (RGEN)
Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA), Repligen (RGEN) and Teva Pharmaceutical (TEVA)
Repligen Analyst Ratings
Buy Rating Reaffirmed for Repligen Amid Strong Growth Prospects and Market Resilience
UBS Maintains Buy on Repligen, Lowers Price Target to $185